Insider Trading Activity Cascadian Therapeutics, Inc. (NASDAQ:CASC) – Insider Bought 5,500 shares of Stock

Insider Trading Activity For Cascadian Therapeutics, Inc. (NASDAQ:CASC)

Story continues below

Scott Dunseth Myers , Insider of Cascadian Therapeutics, Inc. (NASDAQ:CASC) reportedly Bought 5,500 shares of the company’s stock at an average price of 3.74 for a total transaction amount of $20,570.00 SEC Form

Insider Trading History For Cascadian Therapeutics, Inc. (NASDAQ:CASC)

  • On 12/27/2012 Wendy W Warren, Major Shareholder, sold 57,943 with an average share price of $64.30 per share and the total transaction amounting to $3,725,734.90.View SEC Filing
  • On 6/7/2013 Bvf Partners L P/Il, Major Shareholder, bought 214,467 with an average share price of $1.81 per share and the total transaction amounting to $388,185.27.View SEC Filing
  • On 8/1/2013 Bvf Partners L P/Il, Major Shareholder, bought 338,087 with an average share price of $1.74 per share and the total transaction amounting to $588,271.38.View SEC Filing
  • On 8/8/2013 Bvf Partners P/Il, major shareholder, bought 258,361 with an average share price of $1.65 per share and the total transaction amounting to $426,295.65.View SEC Filing
  • On 11/1/2013 Bvf Partners L P/Il, Major Shareholder, bought 129,000 with an average share price of $1.78 per share and the total transaction amounting to $229,620.00.View SEC Filing
  • On 2/20/2014 Daniel K Spiegelman, Director, sold 12,780 with an average share price of $1.96 per share and the total transaction amounting to $25,048.80.View SEC Filing
  • On 7/10/2014 Daniel K Spiegelman, Director, sold 3,403 with an average share price of $1.72 per share and the total transaction amounting to $5,853.16.View SEC Filing
  • Analyst Ratings For Cascadian Therapeutics, Inc. (NASDAQ:CASC)
    These are 1 Hold Rating, 3 Buy Ratings .
    The current consensus rating for Cascadian Therapeutics, Inc. (NASDAQ:CASC) is Buy (Score: 2.75) with a consensus target price of $7.00 , a potential (89.70% upside)

    Analyst Ratings History For Cascadian Therapeutics, Inc. (NASDAQ:CASC)

    • On 12/9/2015 HC Wainwright Reiterated Rating Buy with a price target of $5.00 with a price target of $5.00 to $3.00
    • On 3/11/2017 Jefferies Group LLC Reiterated Rating Buy with a price target of $15.00 to $10.00
    • On 4/21/2017 BTIG Research Initiated Coverage of rating Buy
    • On 5/10/2017 Cantor Fitzgerald Reiterated Rating Hold with a price target of $4.00
    • On 8/9/2017 Cowen and Company Reiterated Rating Buy

    Recent Trading Activity for Cascadian Therapeutics, Inc. (NASDAQ:CASC)
    Shares of Cascadian Therapeutics, Inc. closed the previous trading session at 3.69 up +0.05 1.37% with 239,823 shares trading hands.

    An ad to help with our costs